EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown

Anna Pendrey iD, Javier Sevilla-Martir

Obesity · 2025-11 · 33 (S1) · 57-73

DOI: 10.1002/oby.70029 ↗

At a glance

Übersichtsarbeit in Obesity, published online on 2025-10-08. Written by Anna Pendrey and 1 co-authors. Institution: Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Anti-Obesity Agents, Obesity. Cited 10 times so far (Crossref); 86 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Obesity affects 42% of older adults, with rates continuing to rise. This a complex condition influenced by non‐modifiable as well as modifiable risk factors. The disease can be treated through modifications to diet, physical activity, and behavior and more recently through antiobesity medications (AOMs) and surgery. Treatment must be tailored to individual needs due to age‐related metabolic and physiological changes. This review aimed to identify the suitability of seven FDA‐approved AOMs in the treatment of obesity in older adults.

Methods

A review of AOMs was performed, focusing on their efficacy in weight loss, side effects, and potential health risks in older adults. Studies were selected to later evaluate the overall suitability and safety of these medications.

Results

AOMs can improve cardiovascular outcomes, hypertension, hyperlipidemia, metabolic liver disease, obstructive sleep apnea, and chronic kidney disease. Weight loss in older adults using AOMs is associated with an increased risk of sarcopenia.

Conclusions

From a policy standpoint, ensuring coverage of AOMs for older adults is critical, as these medications help reduce obesity‐related complications. However, increased participation in clinical trials is urgently needed to study the impact of quality of life and outcomes in older adults.

Subjects

MeSH terms (MEDLINE)

Anti-Obesity AgentsObesityHumansAgedWeight LossCardiovascular DiseasesHypertensionSarcopeniaHyperlipidemiasRisk FactorsSleep Apnea, Obstructive

Author keywords

antiobesity medicationsobesityolder adults

Substances

Anti-Obesity Agents

Authors and institutions

  • Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID profiles: Anna Pendrey

Cite

APA

Pendrey, A., & Sevilla-Martir, J. (2025). Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown. Obesity, 33(S1), 57-73. https://doi.org/10.1002/oby.70029

Vancouver

Pendrey A, Sevilla-Martir J. Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown. Obesity. 2025;33(S1):57-73. doi:10.1002/oby.70029

BibTeX
@article{Pendrey2025,
  author = {Pendrey, Anna and Sevilla-Martir, Javier},
  title = {Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {S1},
  pages = {57--73},
  doi = {10.1002/oby.70029}
}
Start for free →